# Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

> **NCT05480449** · PHASE1,PHASE2 · RECRUITING · sponsor: **Stephan Grupp MD PhD** · enrollment: 89 (estimated)

## Conditions studied

- B Cell Acute Lymphoblastic Leukemia (B-ALL)
- B Lineage Lymphoblastic Lymphoma

## Interventions

- **BIOLOGICAL:** Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19)

## Key facts

- **NCT ID:** NCT05480449
- **Lead sponsor:** Stephan Grupp MD PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-20
- **Primary completion:** 2027-09-20
- **Final completion:** 2029-09-20
- **Target enrollment:** 89 (ESTIMATED)
- **Last updated:** 2025-12-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05480449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05480449, "Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05480449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*